OBJECTIVE: To determine the frequency of IgA, in addition to IgM and IgG, anti-beta2-GPI and anticardiolipin (aCL) antibodies in patients with systemic lupus erythematosus (SLE), and to relate the presence of these antibodies to symptoms of antiphospholipid antibody syndrome (APS). METHODS: Sera from 100 blood bank donors (controls) and 48 patients with SLE were tested by ELISA. The same enzyme conjugates were used in the measurement of aCL and anti-beta2-GPI. Medical records were reviewed for the presence of manifestations of APS: arterial occlusion, pulmonary embolism, cerebrovascular accident, transient ischemic attack, venous thrombosis (deep or superficial), hemolytic anemia, thrombocytopenia, repeated fetal loss, leg ulcers, seizures, avascular bone necrosis, cerebritis, or migraine. RESULTS: Above normal levels of antibodies of all 3 isotypes against beta2-GPI were found in 5% of controls and 73% of patients with SLE. Antibodies against cardiolipin in the 2 groups were found in 5 and 37%, respectively. IgA anti-beta2-GPI was found in 2% of controls and 58% of patients with SLE; in contrast, only 2% of patients with SLE had IgA aCL. In the 48 patients studied, thrombosis and fetal loss were present in 10 (Group 1), other manifestations of APS were present in 18 (Group 2), and none in 20 (Group 3). Antibodies to beta2-GPI of all 3 isotypes were found in a higher proportion of APS (Group 1 plus Group 2) (82%) than in Group 3 (50%) (p < 0.01, chi-squared). There was also a significantly higher proportion of patients with elevated anti-beta2-GPI in Group 1 (90%) than in Group 3 (p < 0.02). There was a significantly higher frequency (p < 0.01) and level (p < 0.05) of IgA anti-beta2-GPI in patients with APS than in those with no APS manifestations. Moreover, compared to aCL and with other isotypes of anti-beta2-GPI, the highest antibody levels were observed in IgA antibeta2-GPI. CONCLUSION: The sensitivity of the anti-beta2-GPI antibody test for APS in patients with SLE is significantly increased by measuring IgA, in addition to IgM and IgG isotype.
OBJECTIVE: To determine the frequency of IgA, in addition to IgM and IgG, anti-beta2-GPI and anticardiolipin (aCL) antibodies in patients with systemic lupus erythematosus (SLE), and to relate the presence of these antibodies to symptoms of antiphospholipid antibody syndrome (APS). METHODS: Sera from 100 blood bank donors (controls) and 48 patients with SLE were tested by ELISA. The same enzyme conjugates were used in the measurement of aCL and anti-beta2-GPI. Medical records were reviewed for the presence of manifestations of APS: arterial occlusion, pulmonary embolism, cerebrovascular accident, transient ischemic attack, venous thrombosis (deep or superficial), hemolytic anemia, thrombocytopenia, repeated fetal loss, leg ulcers, seizures, avascular bone necrosis, cerebritis, or migraine. RESULTS: Above normal levels of antibodies of all 3 isotypes against beta2-GPI were found in 5% of controls and 73% of patients with SLE. Antibodies against cardiolipin in the 2 groups were found in 5 and 37%, respectively. IgA anti-beta2-GPI was found in 2% of controls and 58% of patients with SLE; in contrast, only 2% of patients with SLE had IgA aCL. In the 48 patients studied, thrombosis and fetal loss were present in 10 (Group 1), other manifestations of APS were present in 18 (Group 2), and none in 20 (Group 3). Antibodies to beta2-GPI of all 3 isotypes were found in a higher proportion of APS (Group 1 plus Group 2) (82%) than in Group 3 (50%) (p < 0.01, chi-squared). There was also a significantly higher proportion of patients with elevated anti-beta2-GPI in Group 1 (90%) than in Group 3 (p < 0.02). There was a significantly higher frequency (p < 0.01) and level (p < 0.05) of IgA anti-beta2-GPI in patients with APS than in those with no APS manifestations. Moreover, compared to aCL and with other isotypes of anti-beta2-GPI, the highest antibody levels were observed in IgA antibeta2-GPI. CONCLUSION: The sensitivity of the anti-beta2-GPI antibody test for APS in patients with SLE is significantly increased by measuring IgA, in addition to IgM and IgG isotype.
Authors: Darcy S Majka; Kiang Liu; Richard M Pope; Elizabeth W Karlson; Thanh-Huyen T Vu; Marius Teodorescu; Rowland W Chang Journal: Inflamm Res Date: 2013-10 Impact factor: 4.575
Authors: Kun Qian; Fenglong Xie; Andrew W Gibson; Jeffrey C Edberg; Robert P Kimberly; Jianming Wu Journal: J Leukoc Biol Date: 2008-09-10 Impact factor: 4.962
Authors: S Carmo-Pereira; M L Bertolaccini; A Escudero-Contreras; M A Khamashta; G R V Hughes Journal: Ann Rheum Dis Date: 2003-06 Impact factor: 19.103
Authors: Vijaya Murthy; Rohan Willis; Zurina Romay-Penabad; Patricia Ruiz-Limón; Laura A Martínez-Martínez; Shraddha Jatwani; Praveen Jajoria; Alan Seif; Graciela S Alarcón; Elizabeth Papalardo; Jigna Liu; Luis M Vilá; Gerald McGwin; Terry A McNearney; Rashmi Maganti; Prashanth Sunkureddi; Trisha Parekh; Michael Tarantino; Ehtisham Akhter; Hong Fang; Emilio B Gonzalez; Walter R Binder; Gary L Norman; Zakera Shums; Marius Teodorescu; John D Reveille; Michelle Petri; Silvia S Pierangeli Journal: Arthritis Rheum Date: 2013-12